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The Global Burden of Disease (GBD) Study 2010 estimated the GBD attributable to 15 categories of skin disease
from 1990 to 2010 for 187 countries. For each of the following diseases, we performed systematic literature reviews
and analyzed resulting data: eczema, psoriasis, acne vulgaris, pruritus, alopecia areata, decubitus ulcer, urticaria,
scabies, fungal skin diseases, impetigo, abscess, and other bacterial skin diseases, cellulitis, viral warts, molluscum
contagiosum, and non-melanoma skin cancer. We used disability estimates to determine nonfatal burden. Three
skin conditions, fungal skin diseases, other skin and subcutaneous diseases, and acne were in the top 10 most
prevalent diseases worldwide in 2010, and eight fell into the top 50; these additional five skin problems were
pruritus, eczema, impetigo, scabies, and molluscum contagiosum. Collectively, skin conditions ranged from the
2nd to 11th leading cause of years lived with disability at the country level. At the global level, skin conditions were
the fourth leading cause of nonfatal disease burden. Using more data than has been used previously, the burden
due to these diseases is enormous in both high- and low-income countries. These results argue strongly to
include skin disease prevention and treatment in future global health strategies as a matter of urgency.
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INTRODUCTION
Skin disease is one of the most common human illnesses. It
pervades all cultures, occurs at all ages, and affects between
30% and 70% of individuals, with even higher rates in at-risk
subpopulations (NHANES, 1978; Bickers et al., 2006;
Scholfield et al., 2009; Hay and Fuller, 2012). Its detri-
mental effects on health range from physical incapacity to
death (Basra and Shahrukh, 2009). Children and their families
often bear the brunt of this disease burden (Mahe, 2005). The
International Classification of Disease 10 classification of
human disease lists more than 1,000 skin or skin-related
illnesses, a pattern dominated by a few conditions accounting
for most of the skin disease burden. Yet despite this profound
impact, skin disease continues to receive relatively little
attention in the national or global health debate.
Previous attempts have been made to estimate the
prevalence and health impact of skin diseases (Murray and
Lopez, 1996; Global Burden of Disease, 2008) but these have
relied on epidemiological studies, analytical methods, and
disability weighting, which had flaws (Salomon, 2010). The
Global Burden of Disease Study 2010 (GBD 2010) attempts to
rectify these limitations. It provides consistent estimates of
disease prevalence, incidence, mortality, and disability for
261 conditions in 187 countries, by 20-year age groups, by
sex, from 1990 to 2010 (Salomon et al., 2012; Vos et al.,
2012) using systematic reviews of the published literature but
analyzed with the aid of a Bayesian program, which provides
for missing data. Disability was assessed by weighting the
comparative severity of the sequelae of diseases and
estimating their contribution to total health loss over time.
These estimates provide key information to global bodies such
as the World Bank (Murray et al., 2013) and national and
regional institutions by identifying need, informing policy, and
contributing to evidence-based resource allocation. This
paper describes the methods adopted to assess the global
burden of skin disease as part of GBD 2010. Fifteen
common subcategories of skin conditions were selected for
analysis: eczema, psoriasis, acne vulgaris, pruritus (itching
without attributable cause), alopecia areata, decubitus ulcer,
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urticaria, scabies, fungal skin diseases, impetigo, abscess, and
other bacterial skin diseases, cellulitis, viral warts, molluscum
contagiosum/warts, and non-melanoma skin cancer (NMSC).
The remainder of skin diseases was assigned as other skin and
subcutaneous disease. Other key diseases that form a major
part of the work of dermatologists, such as melanoma, were
not included in this analysis.
RESULTS
Skin disease causes a huge burden in the global context of
health. Collectively, skin conditions were the 4th leading
cause of nonfatal burden expressed as years lost due to
disability in 2010; taking into account health loss due to
premature death expressed as disability-adjusted life years
(DALYs), skin remains the 18th leading cause of health burden
worldwide (Tables 1 and 2).
Key prevalence findings
Three skin conditions were in the top 10 most prevalent
diseases globally in 2010—fungal skin diseases (4th global
prevalence¼ 984,290,432), other skin and subcutaneous dis-
eases (5th), and acne vulgaris (8th global prevalence
¼ 645,499,136; Vos et al., 2012). There are further five skin
diseases in the top 50 most common causes of disease—
pruritus (global prevalence¼279,889,120), eczema (global
prevalence¼ 229,761,000), impetigo (global prevalence
¼ 140,495,000), molluscum contagiosum/warts (global
prevalence¼ 122,601,000), and scabies (global prevalence¼
100,625,000).
Previously reported GBD estimated annual deaths for skin
disease included 66.5103 from bacterial skin infections such
as cellulitis and 30.6103 from NMSC (Lozano et al., 2012).
Disability due to skin disease
Collectively, skin conditions ranged from being the 2nd to
11th leading cause of years lived with disability at the country
level for 2010; they range from 3rd to 28th, taking into
account premature deaths.
Supplementary Table S1 online provides the overall skin
condition nonfatal burden per 100,000 population, for 1990
and 2010, by sex. Singapore, Brunei, Hungary, and Sudan
experienced the most nonfatal skin disease burden per capita
in both 1990 and 2010, and Albania, Lithuania, Romania, and
Indonesia the least. Across specific causes, ages, and regions,
burden is higher among females.
In Supplementary Table S2 online, the prevalence of each
cause is provided by region and sex for 2010. Rates differ
substantially by cause across regions: western Europe has the
highest prevalence rate for pruritus but the lowest for scabies
and eastern sub-Saharan Africa has the highest rates of
cellulitis, fungal skin disease, and viral warts but the lowest
rates of urticaria. Figure 1a and b further demonstrate these
regional differences.
The burden of skin conditions, notably acne vulgaris and
decubitus ulcer, show marked age patterns (Figure 2a and b).
The DALY is a measure of health loss taking into account
both nonfatal and fatal health burden (Salomon et al., 2012).
The leading cause of skin condition DALYs is eczema, when
looking across countries, ages, sex, and time because of the
combined high prevalence across geographies and population
and relatively high average disability weight. Supplementary
Tables S3 and S4 online present DALY rates per 100,000
individuals in 2010.
Figure 3 presents the DALY rate per 100,000 individuals in
2010 for all skin conditions combined. Supplementary Figure
S1 online presents the annualized percent change in DALY
rates over the 20-year period from 1990 to 2010.
DISCUSSION
In delivering data on skin disease, the team encountered a
number of methodological problems. The classification of skin
disease was derived from International Classification of
Disease 10, which led to the inclusion of most diseases seen
in dermatology clinics under skin, but other skin problems
under other medical specialities. The best examples of this are
melanoma, which presents in skin clinics but is reported under
cancer, and certain infections such as cutaneous leishmaniasis,
which is reported under infectious disease. The study group
also found, as anticipated, that there were substantial areas of
missing and variable quality data at the regional level. In terms
of age ranges, design of surveys, and even case definitions,
data sources did not follow a uniform approach. Because of the
sheer number and complexity of skin diseases, the analysis
Table 1. DALY ranks when considering skin conditions
collectively
Cause
Global
DALYs
DALY
rank
Ischemic heart disease 129,800,000 1
Lower respiratory infections 115,200,000 2
Cerebrovascular disease 102,200,000 3
Diarrheal diseases 89,523,909 4
Malaria 82,688,806 5
HIV/AIDS 81,549,177 6
Low back pain 80,666,896 7
Preterm birth complications 76,979,669 8
Chronic obstructive pulmonary disease 76,778,819 9
Road injury 75,487,102 10
Major depressive disorder 63,239,334 11
Neonatal encephalopathy (birth asphyxia and
birth trauma)
50,162,510 12
Tuberculosis 49,399,351 13
Diabetes mellitus 46,857,136 14
Iron-deficiency anemia 45,349,897 15
Sepsis and other infectious disorders of the
newborn baby
44,236,488 16
Congenital anomalies 38,890,019 17
Skin conditions 36,921,995 18
Self-harm 36,654,590 19
Falls 35,405,935 20
Abbreviation: DALY, disability-adjusted life year.
Bold values indicate the skin data.
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focused on the most common of these conditions, but future
work must include important disorders such as bullous diseases
and melanoma.
Ideally, an estimate of global burden takes into account the
multiplicity and complexity of the involvement of the skin as a
clinical presentation of disease while recognizing that the skin
involvement is secondary to a generalized process such as
septicaemia. Unfortunately, in GBD 2010, each disease state
was mutually exclusive and collectively exhaustive. This
means, e.g., that lupus erythematosus burden forms part of
‘‘other musculoskeletal disease,’’ with the related dermatolo-
gical manifestations taken into account in the disability
weight. The estimates shown here, therefore, may under-
estimate the total burden of skin diseases. This underestimate
needs to be recognized in any exercise that attributes
resources to the management, including prevention, of disease
on the basis of disability or mortality.
As expected there is variation in the main contributors to the
burden of skin disease between the tropical resource-poor
versus temperate regions. In Oceania, sub-Saharan Africa,
southeast Asia, and the tropical Americas, skin infections
assume a higher proportion of the disease burden (Leekassa
et al., 2005; Steer et al., 2009). The lower burden due to skin
infection in the high-income Asian region highlights the
impact of poverty in addition to climate in defining risk.
However, the high burden of disability related to eczema
remains consistent globally. Although this, in part, reflects the
rising prevalence of atopic dermatitis even in areas where
previously it was uncommon (Haileamlak et al., 2005;
Williams et al., 2008), eczema in adults remains an
important source of disease load. By age 1 year, skin
problems already assume importance as a reason for
disability with high levels seen in teenage years. There is
also a high burden of skin disease in the elderly above the age
of 70 years, where eczema, ulceration, other skin conditions,
NMSC, infections, and pruritus are key problems. Future
revisions of GBD will concentrate on these issues as well as
providing data on new areas of concern such as the growing
evidence of a pathogenetic association between psoriasis and
cardiovascular disease (Ghazizadeh et al., 2010). Beyond this
data, which reflects disease in large populations, very high
prevalence rates of certain skin diseases, particularly
infections, can occur in community or institutional settings;
for instance, scabies is one of the commonest conditions in a
global setting, which can affect more than 60% of the people
living in certain communities (Nair et al., 1977). Therefore, the
impact of skin diseases must be viewed in terms of local
health needs, as regional variations in disability may reflect
differences in both prevalence and availability of health care.
To those in the field of dermatology, it will come as no
surprise that conditions affecting our skin comprise one of the
largest burdens of disease worldwide. However, this can now
be contextualized with all other disease to show that skin
conditions are both widespread and among the most prevalent
and disabling diseases, and a source of considerable loss of
healthy life. Patients attend for treatment at front-line health
facilities, because patients identify an illness that requires
attention. These results confirm why, in all health settings, skin
disease constitutes a major proportion of all diagnoses in
primary care (NHANES, 1978; Scholfield et al., 2009). It also
affirms an urgent need for the inclusion of skin disease
prevention and treatment in national and global health
policies. For dermatologists, there are also two clear
challenges. The first is to prioritize the collection and
analysis of epidemiological and disability data that allow
comparison to be made with other diseases. The second
challenge is to make known and disseminate widely the
obvious conclusion of this study that strategies to manage
and control skin disease are an effective and necessary use of
health resources. Although this is recognized in some skin
diseases (Staples et al., 1998), the results of this study show
that we are merely tackling the tip of the iceberg. There is
huge scope for significant therapeutic advances as well as
preventive strategies operating at international and regional
levels; support by decision-makers is critical in converting
need into practical health policies.
MATERIALS AND METHODS
The overall aim of this study was to estimate the GBD attributable to
skin disease from 1990 to 2010 for 187 countries, by age and sex. The
first step in this estimation was a systematic review to collect data.
Data were analyzed using a Baysian meta-regression tool, described
below, to harmonize discordant data where multiple estimates were
available as well as fill in gaps in geography, time, or age-sex groups,
where data were lacking. The prevalence and incidence estimates
from this process were applied to severity distributions and their
Table 2. YLD ranks when considering skin conditions
collectively
Cause Global YLDs YLD rank
Low back pain 80,666,896 1
Major depressive disorder 63,239,334 2
Iron-deficiency anemia 42,505,250 3
Skin conditions 33,717,725 4
Neck pain 32,650,797 5
Chronic obstructive pulmonary disease 29,420,262 6
Other musculoskeletal disorders 28,247,230 7
Anxiety disorders 26,847,326 8
Migraine 22,362,507 9
Diabetes mellitus 20,791,397 10
Falls 19,479,581 11
Osteoarthritis 17,148,545 12
Drug use disorders 16,434,052 13
Other hearing loss 15,824,531 14
Asthma 13,843,163 15
Alcohol use disorders 13,838,157 16
Road injury 13,489,949 17
Schizophrenia 12,975,089 18
Bipolar affective disorder 12,878,832 19
Dysthymia 11,091,105 20
Abbreviation: YLD, years lost due to disability.
Bold values indicate the skin data.
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related sequelae as well as estimates of magnitude of health loss to
produce burden of non-fatal health loss estimates. A separate strategy
was undertaken to estimate the relatively small burden of mortality,
outlined elsewhere (Lozano et al., 2012).
The GBD 2010 Skin Conditions Expert Group provided the lead in
data collection and disease consultation for all analyses. The group
was recruited from volunteers who responded to an international web-
based invitation for assistance. To ensure uniformity of investigational
approach, training was provided by the Institute of Health Metrics, and
participants used a common procedure manual. The team reviewed
world literature and databases for incidence, prevalence, and remis-
sion rates, using acceptable case definitions and stringent criteria for
validity of data collection. It divided skin diseases into manageable
subcategories from more than 1,000 different disease entities, and
selected the following conditions for analysis on the basis of prevalence,
common case definitions, and data availability: eczema, psoriasis, acne
vulgaris, pruritus, alopecia areata, decubitus ulcer, urticaria, scabies,
fungal skin diseases, impetigo, abscess, and other bacterial skin
diseases, cellulitis, viral warts, molluscum contagiosum, and NMSC.
The categories of disease analyzed were those defined in Interna-
tional Classification of Disease 10 and noted in Supplementary
Table S5 online.
Disease sequelae, the direct disabling consequences of the illness
on the skin, were defined and graded by severity. To maintain
consistency with broader GBD 2010 Study’s definitions, the group
had to limit the definition of disability to that pertaining to the skin in
1
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Figure 1. Skin condition years lost due to disability (YLD) composition by region, 2010. (a) Proportion of total YLD, (b) YLD rate per 100,000. NMSC,
non-melanoma skin cancer.
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terms of symptoms such as itching as well as disfigurement, rather
than expanding disability to include non-health-based quality-of-life
reductions or sequelae captured elsewhere in GBD 2010 (e.g., pain
from psoriatic arthritis, reported under the arthritis burden assessment;
Vos et al., 2012).
Standardized disease definitions were established in several ways.
For instance, with atopic dermatitis, within the broader heading of
eczema, definitions such as the UK working party definition of AD
were used (Williams et al., 1994). Likewise in NMSC histopatholo-
gical confirmation was required. Elsewhere, the diagnosis of a trained
health worker was the standard case definition. The Expert Group
defined sequelae to encompass the symptoms of itch and discomfort
as well as disfigurement and provided lay descriptors for disability to
be used in the GBD 2010 Disability Weights survey in the
establishment of disability weights (Salomon et al., 2012).
Search strategy for identification of studies
Data were collected in a two stage literature review. The expert group
conducted an initial literature review comprised primarily of three
data sources: published articles found in medical literature databases
such as Medline (US National Library of Medicine) and Embase
(Elsevier); national and regional health surveys; and personal com-
munications of unpublished data. The Medline database was
searched using queries composed of MeSH (Medical Subject Head-
ings) terms by which articles were indexed. Queries generally
consisted of the Mesh terms ‘‘Skin disease’’, ‘‘Dermatosis,’’ or
‘‘cutaneous disease’’. For specific disease states, the name of the
condition, plus any variants, was used. For instance for scabies, the
words used were scabies, Sarcoptes, itch mite, Norwegian scabies,
crusted scabies. Data identified under the general MeSH terms but not
included under specific disease headings were recorded under other
skin and subcutaneous diseases.
A secondary literature review was conducted following finalization
of the specific cause categories using PubMed and Google Scholar
for each cause. The details of data retrieval are provided in
Supplementary Table S6 online. The inclusion criteria were studies
that were published between 1980 and 2010 that provided data on
relevant disease incidence or prevalence.
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Studies were excluded for the following reasons:
 Data in study were self-reported unless it had been validated by the
diagnosis of a trained physician
 The study sampled specific groupings
 Occupational groups
 Studies that use data generated by first hospital or clinic presenta-
tion: unless the incidence of those diseases were, in the opinion of
the specialist team, likely to be an accurate reflection of true
incidence
 Non-random samples (i.e., employees, health center patients)
 Studies on specific ethnic or social groups
 Outside the 1980–2010 year range
 Sample size smaller than 100
 Experimental arm of a clinical trial
 Papers that provided estimates rather than data
The reviews were carried out in three stages:
Round (1): Title/abstract review of hits from searches of medical
literature databases.
Round (2): Whole article review of hits remaining after Round 1.
Round (3): Evaluation of articles remaining after Round 2 using
agreed quality criteria.
Most incidence data used for certain skin diseases were obtained
from two medical record sources: (1) inpatient data from Europe,
Latin America, and United States of America, and (2) outpatient
data from Great Britain and United States of America (Royal College
of General Practitioners Research Unit (UK), 2010; Medical
Expenditure Panel Survey, 2010), and (3) in the case of NMSC,
registry data where it included NMSC, e.g., Northern Ireland Cancer
Registry (2010).
The extracted data included as much of the following information
as was available: incidence, prevalence, remission, mortality risk,
severity distribution, ages studied, sexes studied, time period, uncer-
tainty in point estimates, sample size, and any relevant covariates
such as case definition. Ultimately, 895 country-years of data were
used, covering 82 countries. Individual cause models used from 16 to
155 country-years worth of data.
Analysis of data
Skin and subcutaneous disease morbidity was modeled using the
program, DisMod-MR, a negative binomial Bayesian meta-regression
tool, with data gathered (see above). DisMod-MR combines a
compartmental model of disease progression with an age-integrating
mixed-effects negative-binomial model of relevant epidemiological
data. DisMod was used to synthesize all available data and predict
epidemiological parameters of each of the specific causes. Because of
differences in disease etiologies, NMSC was modeled in DisMod-MR
separately as squamous cell carcinoma (SCC) and basal cell carci-
noma (BCC).
There are many parameters that determine the distribution
of skin diseases, from genetic susceptibility to environmental factors.
Social factors such as poverty, affluence, inequality, education, and
access to health care all have an important role in the epide-
miology of skin disease (NHANES, 1978; Williams et al., 1994;
Gibbs, 1996; Figueroa et al., 1998; Scholfield et al., 2009).
Movements of individuals through travel, migration, or war
increase the chance of spread of infectious skin diseases. Non-
infectious skin diseases are also affected by global social and
economic changes including climate change and natural disasters.
The current rise in the burden of NMSC, e.g., is the result
of a complex interaction between societal customs and medical
interventions leading to varied population awareness of risk across the
world.
Where data are lacking, either across geographies or across time,
DisMod utilizes covariates at the study and country level to generate
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predictions. Study-level covariates included such elements as case
definitions and indicators of inpatient or outpatient data; country-
level covariates included average temperature (impetigo and fungal
skin disease; Singh, 1973; Taplin et al., 1973), proportion of the
population with access to sanitation (molluscum contagiosum and
scabies; La Vicente et al., 2009), incidence of melanoma (Gandini
et al., 2005; NMSC) or average sugar consumption per capita (acne
vulgaris; Melnik, 2012).
Additional analytic steps were taken to estimate NMSC prevalence.
Data on BCC duration are highly variable because of differences in
screening, access to health care, diagnosis, workup, and management
protocols. In an attempt to capture this access-related duration, we
created two models of BCC: the first based on an ‘ideal’ average
duration of 1 year, as might be the case in Australia, where full skin
exams are conducted annually, and the second based on a ‘worst-
case’ average duration of 5 years, the time it would take progression
to reach a stage where someone with limited health-care access
would seek care. The prevalence of BCC for a country was a
weighted average of the results of these two models, based on a
measure of health system access. SCC prevalence was estimated in
the standard way described above, but required allocation to stages of
cancer development for disability calculation. Once again, high- and
low-survival curves (based on Surveillance, Epidemiology and End
Results data) were weighted by access to health care. The proportion
alive after 5 years was assigned the disability of diagnosis and
treatment stage of cancer; the proportion dying within 5 years were
assigned the disability of diagnosis and treatment, remission, metas-
tasis, and terminal phases based on SEER data, literature data, and
Skin Expert Group-provided information.
Disability
The GBD 2010 study uses the prevalence estimates produced by this
analytical strategy to estimate years lost due to disability and DALYs.
Both measures are applied to whole populations without differentiat-
ing for potential variables such as social class or environment.
Disability was derived from an analysis of the comparative impact
of the direct disabling consequences of skin disease such as itch and
disfigurement against other conditions through a disability weights
survey, which involved the use of international panels of volunteers, a
telephone-based survey, and a web-based tool. Consistency was
demonstrated among all six sources (Salomon et al., 2012). Estimates
of disease duration and severity distribution were provided by the
dermatology team; the latter was also informed, in part, by data from
the Medical Expenditure Panel Survey, 2000–2009 USA (Medical
Expenditure Panel Survey, 2010). The assigned health states are
shown in Supplementary Table S7 online. For instance, psoriasis
and scabies cases were assigned the sequelae of itch and disfigure-
ment, level 1. Impetigo, abscess, and other bacterial skin diseases,
fungal skin disease, molluscum contagiosum, and viral warts cases
were assigned to the percent asymptomatic from the MEPS analysis,
above, with symptomatic cases assigned the disability weight of a
mild acute infectious disease case. In these diseases, the lay descrip-
tion of itch and disfigurement ultimately used the GBD Disability
Weight Survey, suggested disability beyond that con-
ferred by an average case of these conditions. NMSC disability
combined BCC and SCC disabilities. BCC was considered to have
negligible fatality and disfigurement was the associated disability;
SCC produced fatalities and was associated with disability due to
cancer treatment, remission, and metastases. Table 3 shows average
weight for each cause.
Skin diseases of similar severities and extents will affect different
subject’s lives in strikingly different ways, but for consistency and
because of data limitations, the disability weights were defined as
such. The GBD 2010 Study aimed to capture exclusively health loss,
rather than encompassing reductions in the quality of life.
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